122 related articles for article (PubMed ID: 37968991)
1. Hepatocellular Carcinomas with Concomitant Mutations of TERT, TP53, and CTNNB1: Is There a Role for Artificial Intelligence?
Chillotti S; Maloberti T; Degiovanni A; Malvi D; D'Errico A; de Biase D; Vasuri F
Crit Rev Oncog; 2023; 28(3):31-35. PubMed ID: 37968991
[TBL] [Abstract][Full Text] [Related]
2. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
4. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
[TBL] [Abstract][Full Text] [Related]
5. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
7. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
[TBL] [Abstract][Full Text] [Related]
8. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states.
Biterge Süt B
Comput Biol Chem; 2020 Dec; 89():107404. PubMed ID: 33096424
[TBL] [Abstract][Full Text] [Related]
9. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
10. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection.
Saitta C; Lanza M; Bertuccio A; Lazzara S; Navarra G; Raimondo G; Pollicino T
Cancer Genet; 2015 Oct; 208(10):513-6. PubMed ID: 26341700
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.
Vivekanandan P; Torbenson M; Ramakrishna B
J Gastrointest Cancer; 2011 Mar; 42(1):20-5. PubMed ID: 20963515
[TBL] [Abstract][Full Text] [Related]
13. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
18. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
[TBL] [Abstract][Full Text] [Related]
19. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
20. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]